Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis.
Tiago TorresAnne SohrtUlla IvensAlbert Bosch VilaroJohn StinsonY José Manuel CarrascosaPublished in: Dermatology and therapy (2024)
The results of this analysis demonstrate that, in combination with TCS, tralokinumab and dupilumab have similar efficacy in the treatment of moderate-to-severe AD at 32 weeks of therapy.